Tiotropium
- Generic Name
- Tiotropium
- Brand Names
- Inspiolto Respimat, Spiriva, Spiriva Respimat, Stiolto
- Drug Type
- Small Molecule
- Chemical Formula
- C19H22NO4S2
- CAS Number
- 186691-13-4
- Unique Ingredient Identifier
- 0EB439235F
- Background
Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.
Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than ipratropium.
Tiotropium was granted FDA approval on 30 January 2004.
- Indication
Tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in COPD and to prevent exacerbations of COPD. A combination tiotropium and olodaterol metered inhalation spray is indicated for maintenance of COPD. A tiotropium inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 12 or more years old. A tiotropium metered inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 6 or more years old.
- Associated Conditions
- Asthma, Bronchitis, Bronchoconstriction, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Exacerbation of COPD
- Associated Therapies
- -
Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration
- Conditions
- Interventions
- First Posted Date
- 2010-08-06
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 65
- Registration Number
- NCT01176903
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
Study of a Tiotropium Inhaler For Shortness of Breath in Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2010-07-30
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 34
- Registration Number
- NCT01172925
- Locations
- 🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
- Conditions
- Interventions
- First Posted Date
- 2010-05-11
- Last Posted Date
- 2013-12-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2224
- Registration Number
- NCT01120691
- Locations
- 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom
Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients
- Conditions
- Interventions
- First Posted Date
- 2010-05-10
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 211
- Registration Number
- NCT01119937
- Locations
- 🇯🇵
Novartis Investigative Site, Saitama, Japan
Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 126
- Registration Number
- NCT01072396
- Locations
- 🇺🇸
205.440.1002 Boehringer Ingelheim Investigational Site, Torrance, California, United States
🇺🇸205.440.1018 Boehringer Ingelheim Investigational Site, Hartford, Connecticut, United States
🇺🇸205.440.1015 Boehringer Ingelheim Investigational Site, Jasper, Alabama, United States
Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients
- Conditions
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT01068613
- Locations
- 🇺🇸
Spartanburg Medical Research, 485 Simuel Road, Spartanburg, South Carolina, United States
🇺🇸Advanced Clinical Research Institute, 1211 W. La Palma Ave, Anaheim, California, United States
🇺🇸New Orleans Center for Clinical Research - Knoxville, 1928 Alcoa Highway, Knoxville, Tennessee, United States
Effect of Indacaterol on Inspiratory Capacity (IC)
- Conditions
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 173
- Registration Number
- NCT01012765
- Locations
- 🇩🇪
Novartis Investigative site, Leipzig, Germany
🇩🇪Novartis Investigative Site, Zerbst, Germany
🇩🇪Novartis Investigator Site, Witten, Germany
GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2017-11-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 176
- Registration Number
- NCT00950807
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2011-08-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 25
- Registration Number
- NCT00939211
- Locations
- 🇸🇪
Research Site, Lund, Sweden
1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2012-08-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1066
- Registration Number
- NCT00929110
- Locations
- 🇳🇿
Novartis Investigator Site, Wellington, New Zealand
🇺🇸Novartis Investigative site, Charlotte, North Carolina, United States
🇺🇸Novartis Investigative Center, Crescent Springs, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.